Australia - inglés - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - inglés - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - inglés - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - inglés - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 700 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - inglés - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 500 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - inglés - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - inglés - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 100 g/l - injection, intravenous infusion - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

baxter laboratories pty ltd - n-octyl bicycloheptene dicarboximide; di-n-propyl isocinchomeronate; diethyltoluamide - lotion - n-octyl bicycloheptene dicarboximide bicyclo active 20.0 mg/g; di-n-propyl isocinchomeronate benzene active 15.0 mg/g; diethyltoluamide insect repellent active 40.0 mg/g - household insecticide - pest control - personal use - fly | mosquito | adult mosquitoes

Australia - inglés - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium hydroxide; hydrochloric acid; nitrogen; water for injections; sodium chloride - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - inglés - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; ethanol; nitrogen; water for injections; hydrochloric acid; sodium hydroxide - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).